Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo

Cancer Letters

Volumn 319, Issue 2, 2012, Pages 203-213

  Li, Chia Jung ^a   Chu, Ching Yu ^a   Huang, Lin Huang ^b   Wang, Ming Hseng ^a   Sheu, Lai Fa ^c   Yeh, Jih I ^a,d   Hsu, Hsue Yin ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Buddhist Tzu Chi General Hospital Taichung Branch   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Cisplatin; Mitochondrial apoptotic pathway; Synergism; Triptolide; Xenograft

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; CYCLINE; CYTOCHROME C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TRIPTOLIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DITERPENES; DRUG SYNERGISM; EPOXY COMPOUNDS; HUMANS; MALE; MICE; MICE, SCID; PHENANTHRENES; PHYTOTHERAPY; PLANT EXTRACTS; STOMACH NEOPLASMS; TRIPTERYGIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

TRIPTERYGIUM WILFORDII;

EID: 84862830137     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.006     Document Type: Article

References (35)

1. Varadhachary G., Ajani J.A. Gastric cancer. Clin. Adv. Hematol. Oncol. 2005, 3:118-124.
2. Crew K.D., Neugut A.I. Epidemiology of gastric cancer. World J. Gastroenterol. 2006, 12:354-362.
3. Arkenau H.T. Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J. Cancer Res. Clin. Oncol. 2009, 135:855-866.
4. Macdonald J.S. Gastric cancer-new therapeutic options. N. Engl. J. Med. 2006, 355:76-77.
5. Zhang C.X., Huang S., Xu N., Fang J.W., Shen P., Bao Y.H., Mou B.H., Shi M.G., Zhong X.L., Xiong P.J. Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer. Anticancer Drugs. 2007, 18:581-586.
6. Sikora K. Personalized cancer therapy-the key to the future. Pharmacogenomics 2004, 5:225-228.
7. Wang X., Yan S.K., Dai W.X., Liu X.R., Zhang W.D., Wang J.J. A metabonomic approach to chemosensitivity prediction of cisplatin plus 5-fluorouracil in a human xenograft model of gastric cancer. Int. J. Cancer 2010, 127:2841-2850.
8. Chen B.J. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk. Lymphoma 2001, 42:253-265.
9. Matta R., Wang X., Ge H., Ray W., Nelin L.D., Liu Y. Triptolide induces anti-inflammatory cellular responses. Am. J. Transl. Res. 2009, 1:267-282.
10. Tao X., Younger J., Fan F.Z., Wang B., Lipsky P.E. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum. 2002, 46:1735-1743.
11. Jiang X.H., Wong B.C., Lin M.C., Zhu G.H., Kung H.F., Jiang S.H., Yang D., Lam S.K. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene 2001, 20:8009-8018.
12. Kupchan S.M., Court W.A., Dailey R.G., Gilmore C.J., Bryan R.F. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J. Am. Chem. Soc. 1972, 94:7194-7195.
13. Liu Q. Triptolide and its expanding multiple pharmacological functions. Int. Immunopharmacol. 2011, 11:377-383.
14. Tengchaisri T., Chawengkirttikul R., Rachaphaew N., Reutrakul V., Sangsuwan R., Sirisinha S. Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters. Cancer Lett. 1998, 133:169-175.
15. Yang S., Chen J., Guo Z., Xu X.M., Wang L., Pei X.F., Yang J., Underhill C.B., Zhang L. Triptolide inhibits the growth and metastasis of solid tumors. Mol. Cancer Ther. 2003, 2:65-72.
16. Tang X.Y., Zhu Y.Q., Tao W.H., Wei B., Lin X.L. Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad. Med. J. 2007, 83:338-343.
17. Westfall S.D., Nilsson E.E., Skinner M.K. Role of triptolide as an adjunct chemotherapy for ovarian cancer. Chemotherapy 2008, 54:67-76.
18. Xu B., Guo X., Mathew S., Armesilla A.L., Cassidy J., Darling J.L., Wang W. Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. Cancer Lett. 2010, 291:200-208.
19. Huynh P.N., Hikim A.P., Wang C., Stefonovic K., Lue Y.H., Leung A., Atienza V., Baravarian S., Reutrakul V., Swerdloff R.S. Long-term effects of triptolide on spermatogenesis, epididymal sperm function, and fertility in male rats. J. Androl. 2000, 21:689-699.
20. Ye X., Li W., Yan Y., Mao C., Cai R., Xu H., Yang X. Effects of cytochrome P4503A inducer dexamethasone on the metabolism and toxicity of triptolide in rat. Toxicol. Lett. 2010, 192:212-220.
21. Kim S.J., Han S.W., Oh D.Y., Yi N.J., Kim Y.J., Im S.A., Yoon J.H., Kang G.H., Suh K.S., Bang Y.J., Jang J.J., Kim T.Y. Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma. Anticancer Res. 2010, 30:5245-5250.
22. Sohma I., Fujiwara Y., Sugita Y., Yoshioka A., Shirakawa M., Moon J.H., Takiguchi S., Miyata H., Yamasaki M., Mori M., Doki Y. Parthenolide, an NF-kappaB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics Proteomics 2011, 8:39-47.
23. Fidler J.M., Li K., Chung C., Wei K., Ross J.A., Gao M., Rosen G.D. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol. Cancer Ther. 2003, 2:855-862.
24. Sheu L.F., Chen A., Wei Y.H., Ho K.C., Cheng J.Y., Meng C.L., Lee W.H. Epstein-Barr virus LMP1 modulates the malignant potential of gastric carcinoma cells involving apoptosis. Am. J. Pathol. 1998, 152:63-74.
25. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme. Regul. 1984, 22:27-55.
26. Olive P.L., Banath J.P. The comet assay: a method to measure DNA damage in individual cells. Nat. Protoc. 2006, 1:23-29.
27. Frezza C., Cipolat S., Scorrano L. Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nat. Protoc. 2007, 2:287-295.
28. Huang W.T., Li C.J., Wu P.J., Chang Y.S., Lee T.L., Weng C.F. Expression and in vitro regulation of pituitary adenylate cyclase-activating polypeptide (pacap38) and its type I receptor (pac1-r) in the gonads of tilapia (Oreochromis mossambicus). Reproduction 2009, 137:449-467.
29. Takai N., Ueda T., Nishida M., Nasu K., Narahara H. Synergistic anti-neoplastic effect of AG1478 in combination with cisplatin or paclitaxel on human endometrial and ovarian cancer cells. Mol. Med. Report 2010, 3:479-484.
30. Yunos N.M., Beale P., Yu J.Q., Huq F. Synergism from Sequenced Combinations of Curcumin and Epigallocatechin-3-gallate with Cisplatin in the Killing of Human Ovarian Cancer Cells. Anticancer Res. 2011, 31:1131-1140.
31. Carter B.Z., Mak D.H., Schober W.D., McQueen T., Harris D., Estrov Z., Evans R.L., Andreeff M. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006, 108:630-637.
32. Westerheide S.D., Kawahara T.L., Orton K., Morimoto R.I. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J. Biol. Chem. 2006, 281:9616-9622.
33. Wu P.P., Liu K.C., Huang W.W., Ma C.Y., Lin H., Yang J.S., Chung J.G. Triptolide induces apoptosis in human adrenal cancer NCI-H295 cells through a mitochondrial-dependent pathway. Oncol. Rep. 2011, 25:551-557.
34. Friedberg J.W., Vose J.M., Kelly J.L., Young F., Bernstein S.H., Peterson D., Rich L., Blumel S., Proia N.K., Liesveld J., Fisher R.I., Armitage J.O., Grant S., Leonard J.P. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011, 117:2807-2812.
35. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.